Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by American Century Companies Inc.

American Century Companies Inc. raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 11.2% during the third quarter, HoldingsChannel reports. The firm owned 1,669,565 shares of the company’s stock after purchasing an additional 168,145 shares during the period. American Century Companies Inc.’s holdings in Harmony Biosciences were worth $46,013,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Public Sector Pension Investment Board lifted its position in Harmony Biosciences by 41.6% during the third quarter. Public Sector Pension Investment Board now owns 185,803 shares of the company’s stock worth $5,121,000 after buying an additional 54,605 shares in the last quarter. Capital Fund Management S.A. purchased a new stake in Harmony Biosciences in the 2nd quarter valued at $1,142,000. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Harmony Biosciences by 39.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 234,779 shares of the company’s stock worth $6,471,000 after acquiring an additional 66,236 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Harmony Biosciences by 102.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 65,023 shares of the company’s stock worth $1,792,000 after acquiring an additional 32,923 shares during the period. Finally, Nomura Holdings Inc. boosted its position in shares of Harmony Biosciences by 382.3% during the 2nd quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock valued at $13,364,000 after acquiring an additional 335,237 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of HRMY opened at $28.51 on Friday. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.87. The stock has a market cap of $1.65 billion, a PE ratio of 10.52, a P/E/G ratio of 0.39 and a beta of 0.88. The firm has a 50-day simple moving average of $35.21 and a two-hundred day simple moving average of $33.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.46). The company had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business’s revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.85 earnings per share. As a group, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on HRMY shares. Zacks Research cut shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Needham & Company LLC dropped their price target on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a report on Wednesday, February 25th. Bank of America reduced their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft lowered Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a research report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Hold” and an average target price of $42.67.

Insiders Place Their Bets

In related news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sandip Kapadia sold 20,961 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $35.92, for a total value of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,640 shares of company stock worth $1,932,256 over the last 90 days. 23.60% of the stock is owned by insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.